1266975-27-2 Usage
Uses
Used in Pharmaceutical Industry:
Eplivanserin is used as an antipsychotic agent for the treatment of schizophrenia and other psychotic disorders. Its selective antagonism of the serotonin 5-HT2A receptor is believed to contribute to its therapeutic effects in managing the symptoms of these conditions.
Used in Research and Development:
Eplivanserin is utilized in research settings to further understand the role of the serotonin 5-HT2A receptor in psychotic disorders and to explore its potential applications in the development of new therapeutic agents for these conditions.
Used in Drug Discovery:
As a selective 5-HT2A receptor antagonist, Eplivanserin serves as a valuable compound in drug discovery efforts aimed at identifying novel antipsychotic medications with improved efficacy and reduced side effects compared to existing treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1266975-27-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,6,9,7 and 5 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1266975-27:
(9*1)+(8*2)+(7*6)+(6*6)+(5*9)+(4*7)+(3*5)+(2*2)+(1*7)=202
202 % 10 = 2
So 1266975-27-2 is a valid CAS Registry Number.
1266975-27-2Relevant academic research and scientific papers
PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST
-
, (2012/11/13)
The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof.
Enantioselective synthesis of a dual orexin receptor antagonist
Mangion, Ian K.,Sherry, Benjamin D.,Yin, Jingjun,Fleitz, Fred J.
, p. 3458 - 3461 (2012/08/08)
A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. Key features of the synthesis include a mild copper-catalyzed amination, a highly chemoselective conjugate addition, and a tandem enantioselective transamination/seven-membered ring annulation. The synthesis requires inexpensive starting materials and only four linear steps for completion.
